Skip to main content

3 Result(s)

within Dan T. Vogl Remove this filter Biomedicine Remove this filter English Remove this filter

and

  1. No Access

    Article

    T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

    We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was diagnosed from a thoracic lymph node upon ...

    Guido Ghilardi, Joseph A. Fraietta, James N. Gerson… in Nature Medicine (2024)

  2. Article

    Open Access

    Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)

    Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses are associated with better progression free survival (PFS) and overall survival (OS). To test the...

    Angela Dispenzieri, Amrita Krishnan, Bonnie Arendt, Beth Blackwell… in Blood Cancer Journal (2022)

    Download PDF (899 KB) View Article

  3. No Access

    Article

    NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

    Carl June and colleagues report the results of a phase I/II trial of adoptively transferred engineered T cells in patients with advanced multiple myeloma.

    Aaron P Rapoport, Edward A Stadtmauer, Gwendolyn K Binder-Scholl… in Nature Medicine (2015)